Zobrazeno 1 - 10
of 1 169
pro vyhledávání: '"Relapsing multiple sclerosis"'
Autor:
Bassem Yamout, Raed Alroughani, Jihad Inshasi, Samar Farouk, Fatema Abdulla, Namareq Y. Al-Jarki, Abdulla Alasmi, Sarmad Al Fahad, Jaber Alkhabouri, Khalid Al-Saffar, Beatrice Benedetti, Beatriz Canibano, Dirk Deleu, Ali Hassan, Pournamy Sarathchandran, Ahmed Shatila, Mohammad Abouelnaga, Mona Thakre, Miklos Szolics, Amir Boshra
Publikováno v:
Neurology and Therapy, Vol 13, Iss 5, Pp 1321-1335 (2024)
Abstract Cladribine tablets (CladT), like alemtuzumab, acts as an immune reconstitution therapy. However, CladT is administered orally (alemtuzumab is given by infusion) and without the potential for serious side effects that limit the therapeutic us
Externí odkaz:
https://doaj.org/article/a456e8fecb904caa838b18d50372bc33
Autor:
Jerome de Seze, Dominique Dive, Xavier Ayrignac, Giovanni Castelnovo, Marianne Payet, Amel Rayah, Claudio Gobbi, Patrick Vermersch, Chiara Zecca
Publikováno v:
Neurology and Therapy, Vol 13, Iss 3, Pp 519-533 (2024)
Abstract The number of ageing people with relapsing multiple sclerosis (RMS) is increasing. The efficacy of disease-modifying therapies (DMTs) for RMS declines with age. Also, older persons with MS may be more susceptible to infections, hospitalisati
Externí odkaz:
https://doaj.org/article/da10c1e30c4d425eada5c230eab87fc9
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
ABSTRACTBooster vaccinations against SARS-CoV-2 are recommended 6–12 months after the last dose or infection in elderly and high-risk groups. The present analysis aims to evaluate whether an interval shorter than 12 months is required in multiple s
Externí odkaz:
https://doaj.org/article/8180dc2e2dcc410bb0f523282f04e4e4
Autor:
Stephen L. Hauser, Ludwig Kappos, Amit Bar-Or, Heinz Wiendl, David Paling, Mitzi Williams, Ralf Gold, Andrew Chan, Ron Milo, Ayan Das Gupta, Goeril Karlsson, Roseanne Sullivan, Gordon Graham, Martin Merschhemke, Dieter A. Häring, Patrick Vermersch
Publikováno v:
Neurology and Therapy, Vol 12, Iss 5, Pp 1491-1515 (2023)
Abstract The importance of B cells in multiple sclerosis (MS) has been demonstrated through the advent of B-cell-depleting anti-CD20 antibody therapies. Ofatumumab is the first fully human anti-CD20 monoclonal antibody (mAb) developed and tested for
Externí odkaz:
https://doaj.org/article/eebd67c7598744dda6a94266f7a71dd5
Autor:
Damiano Marastoni, Matteo Foschi, Chiara Eccher, Francesco Crescenzo, Valentina Mazziotti, Agnese Tamanti, Albulena Bajrami, Valentina Camera, Stefano Ziccardi, Maddalena Guandalini, Francesca Bosello, Daniela Anni, Federica Virla, Ermanna Turano, Michele Romoli, Raffaella Mariotti, Francesca Benedetta Pizzini, Bruno Bonetti, Massimiliano Calabrese
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundCladribine has been introduced as a high-efficacy drug for treating relapsing-remitting multiple sclerosis (RRMS). Initial cohort studies showed early disease activity in the first year after drug initiation. Biomarkers that can predict ear
Externí odkaz:
https://doaj.org/article/9d9749d94e1345dbaab41d85453fce9a
Publikováno v:
Frontiers in Neurology, Vol 14 (2023)
Introduction and backgroundAdherence is a critical factor for optimal clinical outcomes in multiple sclerosis (MS) treatment. This study investigated the adherence and clinical outcomes of MS patients treated with subcutaneous (sc) interferon (IFN) (
Externí odkaz:
https://doaj.org/article/80af3589705b49d9a38f98010e9608fd
Autor:
Imtiaz A Samjoo, Christopher Drudge, Sarah Walsh, Santosh Tiwari, Roisin Brennan, Ibolya Boer, Dieter A Haring, Luisa Klotz, Nicholas Adlard, Judit Banhazi
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 12, Iss 7 (2023)
Aim: To assess the relative efficacy of disease-modifying therapies (DMTs) for relapsing multiple sclerosis (RMS) including newer therapies (ozanimod, ponesimod, ublituximab) using network meta-analysis (NMA). Materials & methods: Bayesian NMAs for
Externí odkaz:
https://doaj.org/article/edf22c04e4874c16822477f85d625256
Autor:
Chi-Yan Lee, Koon-Ho Chan
Publikováno v:
Pharmaceutics, Vol 16, Iss 1, p 120 (2024)
Multiple sclerosis is an important neurological disease affecting millions of young patients globally. It is encouraging that more than ten disease-modifying drugs became available for use in the past two decades. These disease-modifying therapies (D
Externí odkaz:
https://doaj.org/article/b61d3127bcee43db8d6ee5c79895a210
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.